PRESS RELEASES

Nyxoah Announces Submission of Draft Registration Statement For Proposed Public Listing in the United States

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Announces Submission of Draft Registration Statement For Proposed Public Listing in the United States

Mont-Saint-Guibert, Belgium – 19 April 2021 – Nyxoah SA (Euronext Brussels: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that it has confidentially submitted a draft Registration Statement on Form F-1 to the Securities and Exchange Commission (the “SEC”) relating to the proposed public offering of its ordinary shares in the United States. The number of ordinary shares to be offered and the price for the proposed offering have not yet been determined. The public offering is expected to take place after the SEC completes its review process, subject to market and other conditions.

This announcement is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, as amended (the “Securities Act”).

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities, if at all, will be made in accordance with the registration requirements of the Securities Act.

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014).

Contacts:
Nyxoah
Fabian Suarez, Chief Financial Officer
[email protected]
+32 10 22 24 55

Gilmartin Group
Vivian Cervantes
[email protected]com

Attachment

Latest News

Huber ลงนามในข้อตกลงเพื่อเข้าซื้อหุ้นที่เหลือในการร่วมลงทุน MAGNIFIN

แอตแลนตา, May 07, 2021 (GLOBE NEWSWIRE) — เมื่อวันที่ 4 พฤษภาคม J.M. Huber Corporation (ต่อไปนี้จะเรียกว่า “Huber”) ได้ลงนามข้อตกลงขั้นสุดท้ายกับ RHI Magnesita (ต่อไปนี้จะเรียกว่า “RHIM”) เพื่อเข้าถือหุ้น 50% ในการร่วมลงทุนแบบ 50/50 ของบริษัท MAGNIFIN Magnesiaprodukte GmbH & Co. KG (ต่อไปนี้จะเรียกว่า “MAGNIFIN”) การทำธุรกรรมนี้คาดว่าจะปิดลงในช่วงครึ่งหลังของปี 2021 ซึ่งอยู่ระหว่างการอนุมัติตามกฎข้อบังคับ แรกเริ่มนั้น Huber ได้รับผลประโยชน์จากการเป็นเจ้าของ MAGNIFIN 50% ซึ่งเป็นส่วนหนึ่งของการซื้อกิจการ Martinswerk จาก Albemarle ในปี 2016 Martinswerk ตั้งอยู่ในเมืองแบร์กไฮม์ ประเทศเยอรมนีกลายเป็นส่วนหนึ่งของหน่วยธุรกิจเชิงกลยุทธ์ (SBU) ของ Huber Engineered Materials (HEM) […]

Philips Annual General Meeting of Shareholders approves all proposals

May 6, 2021 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) announced that today’s Annual General Meeting of Shareholders (2021 AGM) has re-appointed Mr. Marnix van Ginneken as member of the Board of Management and appointed Mrs. Chua Sock Koong and Mrs. Indra Nooyi as members of the Supervisory Board. The other proposals voted on […]

Oculis Selects AGC Biologics’ Heidelberg Facility to Manufacture OCS-02

Seattle, May 06, 2021 (GLOBE NEWSWIRE) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced its partnership with Oculis to manufacture OCS-02, a Phase II investigational drug targeting both Dry Eye Disease and Anterior Uveitis, at its Heidelberg facility. “We are very pleased that Oculis has chosen us to […]

Bombardier Reports First Quarter 2021 Financial Results, Affirms Full Year Financial Guidance and Delivery Outlook

Business jet revenues of $1.3 billion, up 18% year-over-year, mainly driven by a favourable mix of large-cabin aircraft deliveries, including eight Global 7500 aircraft Adjusted EBITDA(1) from continuing operations of $123 million, up 43% year-over-year, reflecting an improved aircraft mix, Global 7500 aircraft learning curve progress and cost structure improvements; adjusted EBIT(1) from continuing operations […]